PTO/SB/21 (08-00)
Approved for use through #0/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Please type a plus sign (+) inside this box → + Application Number 08/323,060 **TRANSMITTAL Filing Date** October 14, 1994 **FORM** First Named Inventor Philip C. Comp SEP 3 0 2002 Group Art Unit (to be used for all correspondence after initial filing) 1644 TECH CENTER 1600/2900 R. Schwadron **Examiner Name OMRF 128** Attorney Docket Number Total Number of Pages in This Submission **ENCLOSURES** (check all that apply) After Allowance Communication Assignment Papers X Fee Transmittal Form to Group (for an Application) Appeal Communication to Board X Fee Attached Drawing(s) of Appeals and Interferences Licensing-related Papers Appeal Communication to Group Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition After Final Proprietary Information Petition to Convert to a Affidavits/declaration(s) Provisional Application Status Letter Power of Attorney, Revocation Change of Correspondence Other Enclosure(s) (please X Extension of Time Request Address identify below): Terminal Disclaimer Return post-card and Itwelve (12) **Express Abandonment Request** references. Request for Refund Information Disclosure Statement CD, Number of CD(s) Certified Copy of Priority Document(s) Remarks Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Holland & Knight LLP Patrea L. Pabst, Reg. No. 31,284 Individual name Suite 2000, One Atlantic Center; 1201 West Peachtree Street, N.E.; Atlanta, GA 30309-3400

September 23, 2002								
	CERTIFICATE OF MAII	LING						
	spondence is being deposited with the United States and to: Commissioner for Patents, Washington, DC 202			dass				
Typed or printed name	Aisha Wyatt							
Signature	4,52 Wyart	Date	September 23, 2002					

Signature

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/17 (11-01)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Lead Religion of information unless it displays a valid OMB control number.

FEE TRANSMITTAL
for FY 2002

Patent fees are subject to annual revision.

🗶 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT

(\$) 55.00

spong to a collection of info	rmation unless it displays a val	id OMB control number.	
Co	ompl t if Known		4
Application Number	08/323,060		
Filing Date	October 14, 1994	RECE	IVF
First Named Inventor	Philip C. Comp		
Examiner Name	R. Schwadron	SEP 3	2002
Group Art Unit	1644		
Attomey Docket No.	OMRF 128	TECH CENTE	ዛ 1600/2

METHOD OF PAYMENT (check all that apply)			FEE CALCULATION (continued)							
Check Credit card Money Other None			3. ADDITIONAL FEES							
Deposit Account:		Large Entity Small Entity								
Deposit Account	it 50-1868		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid		
Number			105	130	205	65	Surcharge - late filing fee or oath	·		
Account Name Holland & Knight LLP		127	50	227	25	Surcharge - late provisional filing fee or cover sheet				
The Commissioner is authorized to: (check all that apply)		139	130	139	130	Non-English specification				
Charge fee(s) indicated below Credit any overpayments			2.520	147 2		For filing a request for ex parte reexamination	į į			
Charge any additional fee(s) during the pendency of this application			112	920*	112	-	Requesting publication of SIR prior to			
		ow, except for the filing fee	112	320	''-	020	Examiner action			
to the above id	entified deposit a		113	1,840*	113 1	,840*	Requesting publication of SIR after			
FEE CALCULATION				440	245	ee	Examiner action  Extension for reply within first month	55.00		
1. BASIC F	LING FEE	-	115	110	215	55	Extension for reply within second month			
Large Entity Fee Fee	Small Entity Fee Fee	Fee Description	116 117	400 920	1	200 460	Extension for reply within third month			
Code (\$)	Code (\$)	Fee Paid					''			
101 740	201 370	Utility filing fee		1,440		720	Extension for reply within fourth month			
106 330	206 165	Design filing fee	128	1,960	228 9	980	Extension for reply within fifth month			
107 510	207 255	Plant filing fee	119	320	219	160	Notice of Appeal	<del></del>		
108 740	208 370	Reissue filing fee	120	320	220	160	Filing a brief in support of an appeal			
114 160	214 80	Provisional filing fee	121	280	221	140	Request for oral hearing			
SUPTOTAL (4) (4)		138	1,510	138 1	,510	Petition to institute a public use proceeding				
SUBTOTAL (1) (\$)			140	110	240	55	Petition to revive - unavoidable			
2. EXTRA C	CLAIM FEES	FOR UTILITY AND REISSUE	141	1,280	241	640	Petition to revive - unintentional			
·		Ext <u>ra Claims below</u> Fee Paid	142	1,280		640	Utility issue fee (or reissue)			
Total Claims Independent	15 - 20	0 x 0 =0	143	460	243	230	Design issue fee			
Claims	1 - 3	0 × 0 = 0	144	620	244	310	Plant issue fee			
Multiple Deper	ndent		122	130	122	130	Petitions to the Commissioner			
			123	50	123	50	Processing fee under 37 CFR 1.17(q)			
Large Entity Fee Fee	Small Entity Fee Fee	Fee Description	126	180	126	180	Submission of Information Disclosure Stmt			
Code (\$)	Code (\$)		581	40	581	40	Recording each patent assignment per	11		
103 18	203 9	Claims in excess of 20			1		property (times number of properties)			
102 84 104 280	202 42 204 140	Independent claims in excess of 3  Multiple dependent claim, if not paid	146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))			
109 84	209 42	** Reissue independent claims	149	740	249	370	For each additional invention to be			
over original patent						examined (37 CFR § 1.129(b))	<del></del>			
110 18 210 9 ** Reissue claims in excess of 20		179	740	279	370	Request for Continued Examination (RCE)				
·		and over original patent	169	900	169	900	Request for expedited examination of a design application			
SUBTOTAL (2) (\$) -0-			Other fee (specify)							
********	r amuiavah asid	if amotor For Pairsons and share	*Radi	iced h	, Basin	Filing	Fee Paid SUBTOTAL (3) (\$) 55.0	oo 11		
**or number previously paid, if greater; For Reissues, see above			1,600		, 20310	y	TOUT OUD TO THE (U)			

SUBMITTED BY		]			Complete (#	applicable)
Name (Print/Type)	Patrea L. Pa	bst Regist (Attorne	tration No. ney/Agent)	31,284	Telephone	(404) 817-8473
Signature	P		<del></del>		Date	09/23/2002

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

IN THE WNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant:

Philip C. Comp

SEP 3 0 2002

**TECH CENTER 1600/2900** 

Serial No.:

08/323,060

Art Unit:

1644

#41/1

Filed:

October 14, 1994

Examiner:

R. Schwadron

For:

"BLOCKAGE OF PROTEIN C ACTIVATION REDUCES MICROVASCULAR

SURGICAL BLOOD LOSS"

Assistant Commissioner for Patents Washington, D.C. 20231

## AMENDMENT AND RESPONSE TO OFFICE ACTION

Sir:

Responsive to the Office Action mailed on May 23, 2002, please amend the application as follows. Submitted with this Amendment and Response is a Petition for Extension of Time, for a small entity, to extend the period for response one month, to and including September 23, 2002; an abstract by Creasey et al. (J. Clin. Invest., 1993, 91(6):2850-2856); an abstract by Griffin et al. (Gene, 1993, 137(1):25-31); an abstract by Oosting et al. (Br. J. Haematol., 1993, 85(4):761-768); an abstract by Nordfang et al. (Thromb. Haemost., 1993, 70(3):448-453); an article by G.J. Broze (Seminars in Hematology, Vol. 29 (3):159-169, 1992); an abstract by Hrkal et al., (J. Histochem. Cytochem Hybridoma, 1991(5)633-640); an abstract by Labarrere et al., (J. Heart Lung Transpant. 1992(2 pt. 1):342-347); an abstract by Toulon et al., (J. Chromatography, 1991(2):493-500); an abstract by Gibson et al., (Thromb. Haemost 1992(5):507-509); an abstract by He et al., (Kidney Int., 1992(5):1170-1174); an abstract by Kristensen et al., (Thromb.